Examining the roles of cannabinoids in pain and other therapeutic indications: a review

Bibliography

• Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nat Prod Rep 1999;16:131-43
   PubMed Web of Science ®Google Scholar
• Allen A, Baker D, Geoffrey WG, The medicinal uses of cannabis and cannabinoids. Pharmaceutical Press; London, UK 2004
   Google Scholar
• Hirst RA, Lambert DG, Notcutt WG. Pharmacology and potential therapeutic uses of cannabis. Br J Anaesth 1998;81:77-84
   PubMed Web of Science ®Google Scholar
• Lucas PG. Regulating compassion: an overview of Canada's federal medical cannabis policy and practice. Harm Reduct J 2008;5:5
   PubMed Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5
   PubMed Web of Science ®Google Scholar
• Maida V, Ennis M, Irani S, Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Support Oncol 2008;6:119-24
   PubMedGoogle Scholar
• Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 2000;60:1303-14
   PubMed Web of Science ®Google Scholar
• Esfandyari T, Camilleri M, Busciglio I, Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 2007;293:G137-45
   PubMed Web of Science ®Google Scholar
• Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987;79:946-52
   PubMed Web of Science ®Google Scholar
• Brenneisen R, Burtstein S, Cabral G, Cannabis and Cannabinoids. Binghamton: The Haworth Integrative Healing Press; 2002
   Google Scholar
• Costa B, Colleoni M, Conti S, Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 2004;369:294-9
   PubMed Web of Science ®Google Scholar
• White HL, Tansik RL. Effects of delta 9-tetrahydrocannabinol and cannabidiol on phospholipase and other enzymes regulating arachidonate metabolism. Prostaglandins Med 1980;4:409-17
   PubMedGoogle Scholar
• Loewe S. Marihuana Activity of cannabinol. Science 1945;102:615-16
   Google Scholar
• Lawrence DK, Gill EW. The effects of delta1-tetrahydrocannabinol and other cannabinoids on spin-labeled liposomes and their relationship to mechanisms of general anesthesia. Mol Pharmacol 1975;11:595-602
   PubMedGoogle Scholar
• Mechoulam R, Gaoni Y. The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 1967;12:1109-11
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Lander N, Varkony TH, Stereochemical requirements for cannabinoid activity. J Med Chem 1980;23:1068-72
   PubMed Web of Science ®Google Scholar
• Howlett AC, Barth F, Bonner TI, International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202
   PubMed Web of Science ®Google Scholar
• Tsou K, Brown S, Sanudo-Pena MC, Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998;83:393-411
   PubMed Web of Science ®Google Scholar
• Galiegue S, Mary S, Marchand J, Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232:54-61
   PubMedGoogle Scholar
• Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 2001;56:1059-68
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-80
   PubMed Web of Science ®Google Scholar
• Kaminski NE, Abood ME, Kessler FK, Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 1992;42:736-42
   PubMed Web of Science ®Google Scholar
• Bouaboula M, Rinaldi M, Carayon P, Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 1993;214:173-80
   PubMedGoogle Scholar
• Gerard CM, Mollereau C, Vassart G, Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991;279:129-34
   PubMed Web of Science ®Google Scholar
• Julien B, Grenard P, Teixeira-Clerc F, Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005;128:742-55
   PubMed Web of Science ®Google Scholar
• Van Sickle MD, Duncan M, Kingsley PJ, Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005;310:329-32
   PubMed Web of Science ®Google Scholar
• Juan-Pico P, Fuentes E, Bermudez-Silva FJ, Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006;39:155-62
   PubMed Web of Science ®Google Scholar
• Idris AI, van 't Hof RJ, Greig IR, Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005;11:774-9
   PubMed Web of Science ®Google Scholar
• Zimmerman S, Zimmerman AM, Laurence H. Effect of delta 9-tetrahydrocannabinol on cyclic nucleotides in synchronously dividing tetrahymena. Can J Biochem 1981;59:489-93
   PubMedGoogle Scholar
• Bouaboula M, Poinot-Chazel C, Bourrie B, Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 1995;312:637-41
   PubMed Web of Science ®Google Scholar
• Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992;89:3825-9
   PubMed Web of Science ®Google Scholar
• Mackie K, Lai Y, Westenbroek R, Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995;15:6552-61
   PubMed Web of Science ®Google Scholar
• Gebremedhin D, Lange AR, Campbell WB, Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol 1999;276:H2085-93
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Ben-Shabat S, Hanus L, Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90
   PubMed Web of Science ®Google Scholar
• Hanus L, Gopher A, Almog S, Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993;36:3032-4
   PubMed Web of Science ®Google Scholar
• Hillard CJ, Campbell WB. Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. J Lipid Res 1997;38:2383-98
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Fontana A, Cadas H, Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994;372:686-91
   PubMed Web of Science ®Google Scholar
• Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. Br J Anaesth 2008;101:59-68
   PubMed Web of Science ®Google Scholar
• Zygmunt PM, Petersson J, Andersson DA, Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999;400:452-7
   PubMed Web of Science ®Google Scholar
• Jarai Z, Wagner JA, Varga K, Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 1999;96:14136-41
   PubMed Web of Science ®Google Scholar
• Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999;57:9-34
   Google Scholar
• Willis WD Jr. The pain system. The neural basis of nociceptive transmission in the mammalian nervous system. Pain Headache 1985;8:20-77
   Google Scholar
• Marshall JS, Stead RH, McSharry C, The role of mast cell degranulation products in mast cell hyperplasia. I. Mechanism of action of nerve growth factor. J Immunol 1990;144:1886-92
   PubMed Web of Science ®Google Scholar
• De Simone R, Alleva E, Tirassa P, Nerve growth factor released into the bloodstream following intraspecific fighting induces mast cell degranulation in adult male mice. Brain Behav Immun 1990;4:74-81
   PubMed Web of Science ®Google Scholar
• Facci L, Dal Toso R, Romanello S, Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995;92:3376-80
   PubMed Web of Science ®Google Scholar
• Mazzari S, Canella R, Petrelli L, N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 1996;300:227-36
   PubMed Web of Science ®Google Scholar
• Godlewski G, Gothert M, Malinowska B. Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex. Br J Pharmacol 2003;138:767-74
   PubMed Web of Science ®Google Scholar
• Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 1999;90:923-31
   PubMed Web of Science ®Google Scholar
• Farquhar-Smith WP, Rice AS. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology 2003;99:1391-401
   PubMedGoogle Scholar
• Farquhar-Smith WP, Jaggar SI, Rice AS. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain 2002;97:11-21
   PubMed Web of Science ®Google Scholar
• Drew LJ, Harris J, Millns PJ, Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci 2000;12:2079-86
   PubMedGoogle Scholar
• Hohmann AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999;822:17-25
   PubMed Web of Science ®Google Scholar
• Millns PJ, Chapman V, Kendall DA. Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones. Br J Pharmacol 2001;132:969-71
   PubMed Web of Science ®Google Scholar
• Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992;48:655-68
   PubMed Web of Science ®Google Scholar
• Herkenham M, Lynn AB, Johnson MR, Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991;11:563-83
   PubMed Web of Science ®Google Scholar
• Martin WJ, Coffin PO, Attias E, Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 1999;822:237-42
   PubMedGoogle Scholar
• Walker JM, Huang SM, Strangman NM, Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 1999;96:12198-203
   PubMed Web of Science ®Google Scholar
• Vaughan CW, Connor M, Bagley EE, Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 2000;57:288-95
   PubMed Web of Science ®Google Scholar
• Martin WJ, Tsou K, Walker JM. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett 1998;242:33-6
   PubMed Web of Science ®Google Scholar
• Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005;168:657-90
   PubMedGoogle Scholar
• McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 2005;10:15-22A
   PubMedGoogle Scholar
• Agurell S, Leander K. Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec 1971;8:391-402
   PubMedGoogle Scholar
• Huestis MA, Sampson AH, Holicky BJ, Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther 1992;52:31-41
   PubMed Web of Science ®Google Scholar
• Watson SJ, Benson JA Jr, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry 2000;57:547-52
   PubMed Web of Science ®Google Scholar
• Wall ME, Sadler BM, Brine D, Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983;34:352-63
   PubMed Web of Science ®Google Scholar
• Jean Gray E, editor. e-Therapeutics [Internet]. Ottawa: Canadian Pharmacists Association, c2009. Available from: https://www.e-therapeutics.ca/. [Last accessed 24 June 2009]
   Google Scholar
• Nahas G, Sutin K, Harvey D, Marihuana and medicine. Totowa: Humana Press; 1999
   Google Scholar
• Agurell S, Halldin M, Lindgren JE, Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986;38:21-43
   PubMed Web of Science ®Google Scholar
• Christensen HD, Freudenthal RI, Gidley JT, Activity of delta8- and delta9-tetrahydrocannabinol and related compounds in the mouse. Science 1971;172:165-7
   PubMed Web of Science ®Google Scholar
• Perez-Reyes M, Timmons MC, Lipton MA, Intravenous injection in man of 9 -tetrahydrocannabinol and 11-OH- 9 -tetrahydrocannabinol. Science 1972;177:633-5
   PubMed Web of Science ®Google Scholar
• Halldin MM, Widman M, Bahr CV, Identification of in vitro metabolites of delta 1-tetrahydrocannabinol formed by human livers. Drug Metab Dispos 1982;10:297-301
   PubMed Web of Science ®Google Scholar
• Martin BR, Wiley JL. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol 2004;2:305-14; discussion 314-16
   PubMedGoogle Scholar
• Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child 1986;61:502-5
   PubMed Web of Science ®Google Scholar
• Meiri E, Jhangiani H, Vredenburgh JJ, Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 2007;23:533-43
   PubMed Web of Science ®Google Scholar
• Lane M, Smith FE, Sullivan RA, Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. Am J Clin Oncol 1990;13:480-4
   PubMed Web of Science ®Google Scholar
• Machado Rocha FC, Stefano SC, De Cassia Haiek R, Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 2008;17:431-43
   PubMed Web of Science ®Google Scholar
• Beal JE, Olson R, Lefkowitz L, Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997;14:7-14
   PubMed Web of Science ®Google Scholar
• Struwe M, Kaempfer SH, Geiger CJ, Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993;27:827-31
   PubMed Web of Science ®Google Scholar
• Gorter R, Seefried M, Volberding P. Dronabinol effects on weight in patients with HIV infection. AIDS 1992;6:127
   PubMed Web of Science ®Google Scholar
• Baker D, Pryce G, Croxford JL, Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000;404:84-7
   PubMed Web of Science ®Google Scholar
• Baker D, Pryce G, Croxford JL, Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001;15:300-2
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26
   PubMed Web of Science ®Google Scholar
• Killestein J, Hoogervorst EL, Reif M, Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002;58:1404-7
   PubMed Web of Science ®Google Scholar
• Vaney C, Heinzel-Gutenbrunner M, Jobin P, Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10:417-24
   PubMed Web of Science ®Google Scholar
• Hagenbach U, Luz S, Ghafoor N, The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007;45:551-62
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela P, Robson P, Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
   PubMed Web of Science ®Google Scholar
• Wissel J, Haydn T, Muller J, Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. J Neurol 2006;253:1337-41
   PubMed Web of Science ®Google Scholar
• Wallace M, Schulteis G, Atkinson JH, Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007;107:785-96
   PubMed Web of Science ®Google Scholar
• Kraft B, Frickey NA, Kaufmann RM, Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 2008;109:101-10
   PubMed Web of Science ®Google Scholar
• Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006;53:769-75
   PubMed Web of Science ®Google Scholar
• Redmond WJ, Goffaux P, Potvin S, Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Curr Med Res Opin 2008;24:1017-24
   PubMed Web of Science ®Google Scholar
• Tseng AH, Harding JW, Craft RM. Pharmacokinetic factors in sex differences in Delta 9-tetrahydrocannabinol-induced behavioral effects in rats. Behav Brain Res 2004;154:77-83
   PubMed Web of Science ®Google Scholar
• Craft RM. Sex differences in behavioral effects of cannabinoids. Life Sci 2005;77:2471-8
   PubMedGoogle Scholar
• Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med 2006;7:25-9
   PubMed Web of Science ®Google Scholar
• Pugh G Jr, Mason DJ Jr, Combs V, Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J Pharmacol Exp Ther 1997;281:730-7
   PubMedGoogle Scholar
• Manzanares J, Corchero J, Fuentes JA. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res 1999;839:173-9
   PubMed Web of Science ®Google Scholar
• Corchero J, Romero J, Berrendero F, Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen. Brain Res Mol Brain Res 1999;67:148-57
   PubMedGoogle Scholar
• Vigano D, Rubino T, Vaccani A, Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) 2005;182:527-36
   PubMedGoogle Scholar
• Williams IJ, Edwards S, Rubo A, Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta9-tetrahydrocannabinol. Eur J Pharmacol 2006;539:57-63
   PubMedGoogle Scholar
• Wilson AR, Maher L, Morgan MM. Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology 2008;55:1219-25
   PubMedGoogle Scholar
• Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006;530:54-8
   PubMed Web of Science ®Google Scholar
• Naef M, Curatolo M, Petersen-Felix S, The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003;105:79-88
   PubMed Web of Science ®Google Scholar
• Skrabek RQ, Galimova L, Ethans K, Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9:164-73
   PubMed Web of Science ®Google Scholar
• Frank B, Serpell MG, Hughes J, Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008;336:199-201
   PubMed Web of Science ®Google Scholar
• Kurzthaler I, Bodner T, Kemmler G, The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol 2005;20:291-3
   PubMedGoogle Scholar
• Wade DT, Robson P, House H, A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17:21-9
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Toperoff W, Vaida F, Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34:672-80
   PubMed Web of Science ®Google Scholar
• Wilsey B, Marcotte T, Tsodikov A, A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008;9:506-21
   PubMed Web of Science ®Google Scholar
• Nurmikko TJ, Serpell MG, Hoggart B, Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133:210-20
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-19
   PubMed Web of Science ®Google Scholar
• Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004;112:299-306
   PubMed Web of Science ®Google Scholar
• Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329:253
   PubMed Web of Science ®Google Scholar
• Mendelson JH, Mello NK. Reinforcing properties of oral delta 9-tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use. Psychopharmacology (Berl) 1984;83:351-6
   PubMed Web of Science ®Google Scholar
• Nakazi M, Bauer U, Nickel T, Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 2000;361:19-24
   PubMedGoogle Scholar
• Ishac EJ, Jiang L, Lake KD, Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 1996;118:2023-8
   PubMed Web of Science ®Google Scholar
• Murphy LL, Gher J, Steger RW, Effects of delta 9-tetrahydrocannabinol on copulatory behavior and neuroendocrine responses of male rats to female conspecifics. Pharmacol Biochem Behav 1994;48:1011-17
   PubMedGoogle Scholar
• Bossong MG, van Berckel BN, Boellaard R, Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009;34:759-66
   PubMed Web of Science ®Google Scholar
• Chen JP, Paredes W, Li J, Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 1990;102:156-62
   PubMed Web of Science ®Google Scholar
• Kathmann M, Bauer U, Schlicker E, Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain. Naunyn Schmiedebergs Arch Pharmacol 1999;359:466-70
   PubMedGoogle Scholar
• Narang S, Gibson D, Wasan AD, Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008;9:254-64
   PubMed Web of Science ®Google Scholar